Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Expected to Announce Earnings of -$0.30 Per Share

Wall Street brokerages expect Verrica Pharmaceuticals Inc (NASDAQ:VRCA) to post ($0.30) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Verrica Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.26). Verrica Pharmaceuticals posted earnings per share of ($1.04) in the same quarter last year, which would suggest a positive year-over-year growth rate of 71.2%. The firm is expected to issue its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Verrica Pharmaceuticals will report full-year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.65) to ($0.90). For the next year, analysts expect that the firm will post earnings of ($2.04) per share, with EPS estimates ranging from ($2.50) to ($1.45). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Verrica Pharmaceuticals.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02).

Several brokerages have weighed in on VRCA. HC Wainwright boosted their price target on Verrica Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 11th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $27.00.

In other news, major shareholder Matt Davidson sold 18,850 shares of the company’s stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $10.16, for a total transaction of $191,516.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 102,507 shares of company stock valued at $990,202. Insiders own 40.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund acquired a new stake in shares of Verrica Pharmaceuticals during the 4th quarter worth $28,000. Rhumbline Advisers acquired a new stake in shares of Verrica Pharmaceuticals during the 1st quarter worth $111,000. Bank of New York Mellon Corp acquired a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter worth $195,000. Geode Capital Management LLC boosted its position in Verrica Pharmaceuticals by 31.7% during the 4th quarter. Geode Capital Management LLC now owns 36,906 shares of the company’s stock worth $300,000 after purchasing an additional 8,885 shares during the period. Finally, Pura Vida Investments LLC boosted its position in Verrica Pharmaceuticals by 219.6% during the 4th quarter. Pura Vida Investments LLC now owns 63,916 shares of the company’s stock worth $521,000 after purchasing an additional 43,916 shares during the period. Institutional investors and hedge funds own 34.31% of the company’s stock.

VRCA traded up $0.11 during trading on Friday, hitting $9.79. The company’s stock had a trading volume of 62 shares, compared to its average volume of 44,916. The business has a 50 day simple moving average of $8.79. The stock has a market cap of $243.72 million and a PE ratio of -6.86. Verrica Pharmaceuticals has a twelve month low of $6.44 and a twelve month high of $20.30.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Recommended Story: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.